In recent years, targeted therapy against lung cancer is widely used in clinics, such as tyrosine kinase inhibitors (TKIs) and epidermal growth factor receptor (EGFR) inhibitors 4, 5, but the five-year survival rate of lung cancer is still low due to the late-stage diagnosis and metastasis, as well as drug resistance 6. Here, EGFR is linked to lung cancer.